New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
16:21 EDTTIE, JCP, GILD, NYX, LUK, GSK, UNH, PCP, JEF, CLVS, SRPT, TRVOn The Fly: Closing Wrap
Stocks on Wall Street finished virtually unchanged as the holiday held trading volumes down. With bond markets and banks being closed for Veterans Day the averages stayed within a narrow range on either side of the flat line... ECONOMIC EVENTS: In the U.S. no economic data was released. In Asia, Chinaís exports rose 11.6% in October, topping forecasts. However, Japan's gross domestic product fell an annualized 3.5% in the three months through September and economists predict the nationís economy will shrink again in the next quarter, meaning it will have moved into recession... COMPANY NEWS: Leucadia National (LUK) agreed to acquire the remaining 71.4% of Jefferies (JEF) it doesn't own for $17.66 per share in an all stock transaction and shares of Jefferies rose $2.00, or 14.02%, to $16.27. Also, after Friday's closing bell, Precision Castparts (PCP) announced a deal to buy Titanium Metals (TIE) for $16.50 per share, or $2.9B. Shares of Titanium Metals closed up $4.93, or 42.61%, to $16.50 and shares of Precision Castparts also advanced $8.36, or 4.88%, to $179.69... The NYSE (NYX) said that it is continuing to investigate issues that affected trading in 216 symbols. Affected symbols included Dow members Travelers (TRV) and United Health Care (UNH)... MAJOR MOVERS: Among the notable gainers was Gilead (GILD), up $8.91, or 13.71%, to $73.92 after the company reported that it did not detect hepatitis C virus, or HCV, in the RNA of 25 HCV patients four weeks after they were treated with the company's investigational drug. Also higher were shares of Sarepta Therapeutics (SRPT), up $4.38, or 19.25%, to $27.13 after a JMP Securities analyst said a Duchenne muscular dystrophy treatment developed by GlaxoSmithKline (GSK) that will compete with Sarepta's drug is unlikely be approved until 2014 or 2015. Among stocks trading lower was J.C. Penney (JCP), down $2.67, or 12.94%, to $17.97 as the stock continued its downtrend after last week's earnings miss and was downgraded to Underperform from Neutral at Credit Suisse. Also lower were shares of Clovis Oncology (CLVS), down $8.99, or 41.83%, to $12.50 after the company reported negative results from a cancer drug trial and said it would suspend all development of the drug pending further evaluation of the data... INDICES: The Dow gained 1.31, or 0.01%, to 12,816.70; the Nasdaq fell 0.61, or 0.02%, to 2,904.26; and the S&P 500 added 0.15, or 0.01%, to 1,380.00.
News For JEF;LUK;TIE;PCP;NYX;TRV;UNH;GILD;SRPT;GSK;JCP;CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 19, 2015
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
August 18, 2015
10:19 EDTPCPOptions with increasing implied volatility
Subscribe for More Information
10:13 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTPCPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:57 EDTUNHMagellan Iowa loss largely priced into shares, says Jefferies
Subscribe for More Information
06:12 EDTPCPPrecision Castparts downgraded to Neutral from Buy at UBS
UBS analyst David Strauss downgraded Precision Castparts (PCP) to Neutral saying a higher competing takeover bid to Berkshire Hathaway's (BRK.A) is unlikely to emerge. The analyst lowered his price target for Precision Castparts to $235 from $244.
August 17, 2015
16:12 EDTUNHMagellan drops after Iowa picks four others for Medicaid
Subscribe for More Information
15:57 EDTUNHUnitedHealth up 2.4% after being awarded Iowa healthcare contract
15:55 EDTUNHWellCare, Amerigroup, UnitedHealth, AmeriHealth awarded Iowa healthcare contract
Reference Link
12:23 EDTJCPStocks with call strike movement; Netflix J.C. Penney
Netflix (NFLX) January 150 call option implied volatility increased 2% to 48, J.C. Penney (JCP) January 10 call option implied volatility increased 1% to 40 according to IVolatility.
10:55 EDTPCPOptions with increasing implied volatility
Subscribe for More Information
10:24 EDTJCPAnalyst notes give J.C. Penney shares a boost
Subscribe for More Information
10:21 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
10:09 EDTJCPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:26 EDTJCPOn The Fly: Pre-market Movers
HIGHER: AVEO (AVEO), up 119.7% after announcing licensing agreement with Novartis (NVS)... OHR Pharmaceutical (OHRP), up 24.9% after Soros reports new stake in company in 13F filing... Kite Pharma (KITE), up 4.6% after saying patient death unrelated to KTE-C19... Tesla (TSLA), up 5.5% after price target raised to $465 from $280 at Morgan Stanley... Mobileye (MBLY), up 2.7% after price target raised to $80 from $71 at Morgan Stanley... J.C. Penney (JCP), up 1.5% after being initiated with a Buy at B. Riley and Piper Jaffray raised its price target to $17 from $15. DOWN AFTER EARNINGS: Estee Lauder (EL), down 2.1% after reporting quarterly results and giving guidance for first quarter and fiscal 2016. ALSO LOWER: KKR (KKR), down 3.3% after Samson enters restructuring deal and expects to file for bankruptcy within 30 days... Aquinox (AQXP), down 4.7% after Lloyd Mackenzie, vice president - Technical Operations and Planning, disclosed late Friday the sale of 35,887 shares worth over $670,000 in a sale related to the exercise of options.
07:17 EDTJCPJ.C. Penney initiated with a Buy at B. Riley
B. Riley initiated J.C. Penney with a Buy rating and $12.50 price target. The firm sees positive business trends, despite industry headwinds, and numerous opportunities for margin recovery.
06:51 EDTJCPJ.C. Penney price target raised to $17 from $15 at Piper Jaffray
Subscribe for More Information
06:22 EDTSRPTPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
05:44 EDTJCPJ.C. Penney initiated with a Buy at B. Riley
B. Riley analyst Jeff Van Sinderen started shares of J.C. Penney with a Buy rating and $12.50 price target. The retailer closed Friday at $8.52. Sinderen views Penny as a "speculative turnaround" story and believes the company's "substantial" real estate assets partially offset its heavy debt load.
August 16, 2015
13:20 EDTPCPBerkshire Hathaway could see boost from Castparts deal, Barron's says
Berkshire Hathaway's (BRK.A, BRK.B) agreement to acquire Precision Castparts (PCP) looks like a "good -- not great" deal for Berkshire and could yield attractive returns for the company, Barron's contends in its 'Follow Up' column. Reference Link
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use